FDA
-
-
-
-
-
-
-
Osmotica Pharmaceuticals plc Closes Sale of Legacy Business to Alora Pharmaceuticals, LLC
-
-
-
-
-
-
-
Osmotica Pharmaceuticals plc Reports Fourth Quarter and Full Year 2020 Results and Provides Business Update
-
-
-
-
-
-
-
Osmotica Pharmaceuticals Plc (OSMT) Subsidiary, RVL Pharma, Reports Publication of Pooled Data Analysis from Two Ph. 3 Clinical Trials of Upneeq
-
-
-
-
-
-
-
Santen and RVL Pharmaceuticals, Inc., an Osmotica Company, Enter into an Exclusive License Agreement in Japan, Asia, and EMEA for RVL-1201, a First-in-Class Treatment for Acquired Blepharoptosis
-
-
-
-
-
-
-
Osmotica Pharmaceuticals plc Receives FDA Approval for Upneeq™ (oxymetazoline hydrochloride ophthalmic solution), 0.1% for Acquired Blepharoptosis (Droopy Eyelid) in Adults
-
-
-
-
-
-
-
Osmotica Pharmaceuticals plc Reports Fourth Quarter and Full Year 2019 Results and Provides Business Updates
-
-
-
-
-
-
-
Osmotica Pharmaceuticals plc (OSMT) Announces Michael J. DeBiasi to Board
-
251,890 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All